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Summary
Purpose: In Genetic Absence Epilepsy Rats from Strasbourg (GAERS), age-related
absence seizures start to appear from postnatal day (PN) 30 concomitant with ‘spike
and wave discharges’ (SWDs) appearing on cortical EEG recordings. The aim of this
study was to investigate the effect of early chronic levetiracetam (LEV) treatment on
the development of SWDs in young and adult GAERS.
Methods: From PN23 until PN60, LEV (54 mg/kg, i.p.) was administered once daily to
GAERS (n = 8), while control GAERS (n = 7) received saline (0.9% NaCl, i.p.). All
animals were implanted with four epidural EEG electrodes at PN51. EEG was recorded
for 3 h daily, during the last 4 days of the treatment (PN57-PN60) and during 4
additional days after treatment had been terminated (PN61—PN64). The animals were
monitored again at the age of 4 months (PN120—PN124), about 2 months after the last
administration of LEV.
Results: During treatment, epileptiform events in the LEV group were significantly
reduced (62%, P < 0.05) in comparison with the control group. During the following 4
days, epileptiform events were reduced in the LEV group, with an average difference
of 53% (P = 0.064). Once the animals had reached adult age, there was no difference in
epileptiform events between the LEV group and controls.
Conclusion: In this study, chronic LEV administration induced a reduction in epilepti-
form events in young GAERS. This effect persisted to some extent after treatment* Corresponding author. Tel.: +32 9 2403355; fax: +32 9 2403355.
E-mail address: Stefanie.Dedeurwaerdere@UGent.be (S. Dedeurwaerdere).
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Every year the incidence of new epilepsy cases is
between 26 and 70 per 100,000.1 Despite the devel-
opment of new pharmacological treatments,
approximately one-third of epilepsy patients do
not respond to anti-epileptic drugs (AEDs), and
are referred to as refractory patients.2 Treatments
with anti-epileptogenic potential could modulate
the processes underlying the development of epi-
lepsy. Anti-epileptogenic properties have been
attributed to some AEDs like valproate,3 lamotri-
gine,4 and pregabalin5 as well as to vagus nerve
stimulation.6 Anti-epileptogenic effects of levetir-
acetam (LEV) in addition to anti-epileptic effects
have been reported to appear in the rat amygdala
kindling model for temporal lobe epilepsy4,7 and the
Spontaneously Epileptic Rat (SER), a model of pri-
mary generalized epilepsy.8
LEV is a novel well-tolerated AED approved as an
adjunctive therapy for epilepsy patients with
refractory partial seizures with or without second-
ary generalization.9,10 LEV has an anti-epileptic
effect in a broad range of animal models mimicking
both partial11—13 and generalized epilepsy in man11
including Genetic Absence Epilepsy Rats from Stras-
bourg (GAERS).14 In contrast, LEV revealed no effect
in the two conventional screening tests, namely the
maximal electroshock and pentylenetetrazol mod-
els.11 The mechanism of action of LEV differs from
other AEDs and is as yet not fully elucidated.
Studies conducted on AEDs administered during
the process of epileptogenesis have so far focused
on animal models of acquired symptomatic epi-
lepsy.5,15 In contrast, animal models of genetic
idiopathic epilepsy have only been used scarcely.
This study was stimulated by the ability of LEV to
suppress seizure activity in animal models mimick-
ing absence epilepsy in man.14,16,17 Moreover, in a
previous pilot study of chronic LEVadministration to
young GAERS, a preliminary indication of an anti-
epileptogenic effect was found.16 Indeed, it was felt
that investigating the effect of chronic LEV treat-
ment in young GAERS could provide new insights and
strategies for the treatment of epilepsy.
GAERS is an isomorphic and predictive model of
absence epilepsy. The hallmark is the appearance of
bilateral generalized ‘spike and wave discharges’
(SWDs) on the cortical EEG recordings during spon-taneous absence seizures characterized by beha-
vioral arrest. The first SWDs appear around
postnatal day (PN) 30—PN40 and at the age of 4
months 100% of the GAERS have SWDs, which persist
throughout the lifespan of the animal.18
In the present study, we have investigated the
effect of LEV on the age-related development of
SWDs in GAERS by chronic administration of LEV
(PN23—PN60) starting before the age of occurrence
of SWDs. The effect of early chronic LEV adminis-
tration on the development of SWDs was evaluated
in young GAERS during treatment (PN57—PN60),
immediately after treatment termination (PN61—
PN64) and 2 months after the last LEV injection (age
4 months), when brain maturation was achieved and
SWDs recorded on cortical EEG were numerous.Methods
Animals
Fifteen GAERS were used in this study. The animals
were born and raised under environmentally con-
trolled conditions (12-h light/12-h dark cycles,
lights on at 7:00 a.m., 20—22 8C) with food and
water ad libitum at the animal facility of the Ghent
University Hospital. All animals were treated
according to the guidelines approved by the Eur-
opean Ethics Committee (decree 86/609/CEE). The
study protocol was approved by the Animal Experi-
mental Ethical Committee of Ghent University Hos-
pital.
Surgery
The pups (n = 15) were randomly assigned to the two
treatment groups: LEV and control group. LEV
(54 mg/kg, provided by UCB Pharma, Belgium)
was dissolved in saline (0.9% NaCl) and injected
intraperitoneally (i.p.) in a dose-volume of 2 ml/
kg body weight, whereas control rats received an
equivalent dose-volume of saline. From PN23 until
PN60, LEV was administered once daily to eight
GAERS, while the control GAERS (n = 7) received
saline. All animals were weighed daily.
At age PN51, four epidural EEG stainless steel
screw electrodes were bilaterally implanted over
the fronto-parietal cortex of all 15 animals. The ratscessation (PN61—PN64), which might indicate a slowing down of epileptogenic
processes. However, at the age of 4 months all animals revealed a similar expression
of epileptiform discharges.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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7.5 mg/kg, respectively, i.p.) and additional keta-
mine (5 mg/kg, i.p.) was given when sensorial pain
stimuli, by squeezing the footpad, elicited motor
reflexes. One epidural electrode was positioned on
the left side of the skull at height of the frontal
cortex (AP = +2 mm, ML = +1.2 mm, referred to
bregma) and one was placed on the right side of
the parietal cortex (AP = 2 mm, ML = 1.2 mm,
referred to bregma). The reference electrode was
placed at lambda with the ground electrode on the
left side of lambda (ML = +1.2 mm, referred to
lambda). The EEG electrodes were fixed on the skull
of the rat with acrylic cement. Lidocaine gel (2%)
was applied at the incision wound and the rats were
placed under a heating lamp until they had recov-
ered from anesthesia.
EEG recording
EEG was recorded by means of a H2O
TM
portable
digital 32-channel EEG-recorder (Telefactor Corpora-
tion, USA). To avoid any interference with the circa-
dian cycle, all recordings were performed during
daytime (light period) starting at 10:00 a.m. in awake
and freely moving animals.19 Every 10 min, a stan-
dardized sound stimulus was provided to prevent the
rats from falling asleep.14,20 During the recording
sessions, the rats were continuously observed.
Effect of early chronic LEV administration
on epileptiform events in young GAERS
(PN57—PN64)
One week after surgery, the animals were placed in
the EEG recording chambers and stayed there from
PN56 (1 day before the start of the EEG recordings)
until PN64 with food and water ad libitum. During
the last 4 days of the treatment (PN57—PN60), EEG
was recorded for 3 h daily. In this period, LEV or
saline was injected 1 h after the start of the EEG
recording. From PN61 on, treatment was halted,
animals (controls and LEV group) received no longerFigure 1 Study design. LEV (45 mg/kg, i.p.) was administere
last 4 days of the treatment (PN57—PN60), EEG was recorded
PN64), treatment was terminated and EEG was again recordinjections and EEG was recorded during 4 additional
days (PN61—PN64), 3 h daily (Fig. 1). The EEG was
recorded on several days to have a more robust
dataset on the effect of LEV in these young animals.
Epileptiform events in young GAERS (PN57—PN64)
were quantified by means of visual inspection of the
EEG using TWINTM off-line EEG analysis (Telefactor
Corporation, USA) by an experienced electroence-
phalographer (SD). Young GAERS (under the age of 4
months) may not all have developed typical SWDs
yet or have infrequent SWDs.18 For quantification
purposes, epileptiform events were classified into
two closely related types, because the morphology
of SWDs in young GAERS was found to be less pro-
nounced and more variable when compared with
SWD patterns in adult GAERS (Fig. 2): (i) typical
SWDs also present in adult GAERS (amplitude: >3
times baseline; peak frequency: 7—12 Hz; duration:
>0.5 s) and (ii) SWD-like activity, which we have
termed ‘short irregular spike and wave discharges’
(SISWDs), with clear spike and wave aspects char-
acterized by lower amplitude (<3 times baseline
amplitude) or lower peak frequency (5—7 Hz) and
shorter in duration (<2 s). Only the numbers of
different SWD types (SWDs and SISWDs) per hour
were used as dependent values. The durations of
SWDs and SISWDs were still very short in these young
animals; therefore, relevant differences in dis-
charge duration between treated and control ani-
mals could not be detected.
Evaluation of SWDs in adult GAERS (age 4
months) after chronic LEV treatment
during early life
About the age of 4 months (range PN120—PN124),
EEG was recorded for 1 day (duration of recording
between 6 and 8 h) in 15 animals. For the analysis of
the SWDs on the EEG of the adult GAERS, a pre-
viously described and validated detection software
package was used.21 Once a list of marked time
instances was obtained by the detection method,
a number of post-processing steps were performedd once daily at 11:00 a.m. from PN23 to PN60. During the
for 3 h starting at 10:00 a.m.; the following 4 days (PN61—
ed for 3 h a day.
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Figure 2 Different types of SWDs. (A) Typical adult SWD
(amplitude: >3 times baseline amplitude; peak fre-
quency: 7—12 Hz; duration >0.5 s); (B) SWD-like events,
i.e., SISWDs in young GAERS (PN57—PN64) consist of irre-
gular short discharges, with clear spike and wave aspects
characterized by lower amplitude (<3 times baseline
amplitude) or lower peak frequency (5—7 Hz).by the software package: detections lasting less
than 0.5 s were discarded and two detections less
than 1 s apart were taken together. SWDs detected
by the software package were visually confirmed. In
these animals, both the number per hour and mean
duration of the SWDs during the recording hours
were calculated as well as the cumulative duration
of the SWDs per hour (summation of the duration of
all SWDs per hour).
The software package specifically developed for
the detection of SWDs was not appropriate for the
scoring of the more irregular variant of the SWDs
(SISWDs). Hence, the EEG was visually inspected for
SISWDs, fulfilling the conditions described above,
and the number per hour was calculated.
Statistical analysis
In young GAERS, statistical analysis was performed
on both pooled and unpooled data. Data could be
pooled after exclusion of interactions (hour  treat-
treatment and day  treatment) by ANOVA with
repeated measurements. The number of SWDs and
SISWDs per 3 h was taken together; this was termed
the number of epileptiform events. Statistical ana-
lysis was also performed on unpooled data, which
consisted of the number of typical SWDs and SISWDs
per hour at the different time points during a totalrecording time of 24 h (3 h a day, during 8 consecu-
tive days).
For the inter-group comparison between the LEV
and control group the Mann—Whitney U-test was
used. For the intra-group comparisons within the
LEVand control group, a Friedman test was utilized.
For the intra-group comparison between the mean
number of epileptiform events on the two time
points: during the last 4 days of treatment
(PN57—PN60) and during the following 4 days after
treatment had been terminated (PN61—PN64), a
Wilcoxon signed rank test was used.
Through the further course of this paper (Results
and Discussion Sections), the results obtained in
young GAERS will be presented and discussed
according to the recording periods: (a) the last 4
days of the treatment (PN57—PN60) and (b) the
following 4 days after treatment cessation (PN61—
PN64).
In adult rats, the Mann—Whitney U-test was used
to compare the number per hour, the mean duration
and the cumulative duration/hour of the SWDs
between the LEV and control group. For SISWDs,
the number per hour was compared between the
LEV and control group using the Mann—Whitney U-
test.
All statistical tests were performed utilizing the
statistical software package SPSS 12. Data are pre-
sented as the mean  the standard error of the
mean (S.E.M.), and the significance level has been
set at a = 0.05.Results
Chronic administration of LEV during 38 days in
young GAERS (PN23—PN60) did not induce growth
changes. Normal body weight in LEV-treated GAERS
(157  8 g for males and 144  10 g for females at
PN60) was achieved in comparison with the control
group (140  15 g for males and 121  6 g for
females at PN60) treated with saline (NS, Student’s
t-test).
Effect of early chronic LEV administration
on epileptiform events in young GAERS
(PN57—PN64)
LEV-treated rats (n = 8) showed less SWDs and
SISWDs than control rats (n = 7) during treatment
and also during the 4 days after the discontinuation
of the treatment. During this 8-day recording per-
iod, typical SWDs were observed in three control
rats. Only one of these rats had frequent (12  2 per
hour) SWDs on the EEG, which were short in duration
(1.6  0.2 s). None of the LEV-treated rats had typi-
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significant differences in SWDs between LEV and
control group. SISWDs were observed in all rats.
These SWD-like events were short lasting (<1.5 s)
in the LEV and in the control group.
Effect of chronic LEV administration on
epileptiform events during the last 4 days of
the treatment period (PN57—PN60)
During LEV treatment (PN57—PN60), the mean num-
ber of epileptiform events (pooled data) was 62%
lower (P < 0.05, Mann—Whitney U-test) in the LEV
group. The control group had a mean number of
86  18 epileptiform events per 3 h, whereas this
figure in the LEV group was 33  11. Significant
differences could also be found in the number of
SISWDs (up to 81%) between LEV and control group
on different time points during treatment (Fig. 3).
Also during the pre-injection hours (PN57—PN60),
SISWDs were significantly lower in the LEV group
(8  2; 6  2; 4  2 and 7  3) than in the control
group (28  8; 32  6; 17  6 and 20  4) (Fig. 3).
Pre- and post-injection hours differed signifi-
cantly in treated animals on PN59 and PN60 (Fried-
mand test). Surprisingly, the number of SISWDs in
the post-injections hours was higher than in the pre-
injection hour in the LEV-treated group (Fig. 3).
However, a trend of a higher number of SISWDs in
the post-injection hours was also present in the
control group on PN59 (P = 0.066; Friedman test).
No differences were found between the 4 indivi-
dual days during treatment (PN57—PN60) within LEV
and control group (data not shown, Friedman test).Figure 3 Effect of chronic LEVadministration (PN23—PN60) o
in the LEV group treated with LEV (solid bars, n = 8) and in the
treatment (PN57—PN60) and after treatment discontinuatio
SISWDs = short irregular spike and wave discharges; PN = post
2 h = first post-injection hour or second recording hour; 3
Differences between control and LEV group are assessed us
the three different hours within the groups is assessed usingEffect of chronic LEV administration on
epileptiform events after treatment cessation
(PN61—PN64)
When treatment was discontinued (PN61—PN64),
there was a borderline missed reduction of 53% in
the mean number of epileptiform events (P = 0.064,
pooled data, Mann—Whitney U-test) in the LEV
group compared with the control group. The control
group had a mean number of 73  14 epileptiform
events per 3 h, whereas this figure in the LEV group
was 34  8. However, significant differences could
be found in SISWDs (up to 66%) between LEV and
control group at different separate time points
(unpooled data, Fig. 3).
After treatment had been stopped, there were no
differences between the recording hours within the
LEV and the control group (Friedman test).
Within LEV and control group, there was a sig-
nificant difference between the 4 days after treat-
ment cessation (pooled data, Friedman test); this
was manifested by an increase in the number of
epileptiform events on the last 2 days of the record-
ing period. In the LEV group, these number of
epileptiform events on PN61—PN64 were, respec-
tively, 25  8, 23  7, 40  10 and 48  9. In the
control group, these figures were 52  14, 57  10,
94  19 and 88  19.
The Wilcoxon signed rank test did not reveal
differences between the mean number of epilepti-
form events during treatment period and after
treatment cessation in both groups (86  13 versus
73  14 for the control group and 33  11 versus
34  6 for the LEV group).n SISWDs in young GAERS (PN57—PN64). Number of SISWDs
control group treated with saline (open bars, n = 7) during
n (PN61—PN64). Data are expressed as mean  S.E.M.;
natal day; 1 h = pre-injection hour or first recording hour;
h = second post-injection hour or third recording hour.
ing the Mann—Whitney U-test and differences between
the Friedman test; *P < 0.05; **P < 0.01.
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Figure 4 Evaluation of epileptiform events in adult
GAERS (age 4 months) after chronic LEV treatment during
early life. (A) Number of SWDs and SISWDs per hour, (B)
mean duration of SWDs (s) and (C) cumulative duration of
SWDs per hour (s/h) in the LEV group (solid bars, n = 8) and
in the control group (open bars, n = 7). Data are expressed
as mean  S.E.M.Evaluation of SWDs in adult GAERS (age 4
months) after chronic LEV treatment
during early life
At the age of 4 months all animals had typical SWDs.
EEG recordings showed no significant difference
between the LEVand control group in number, mean
duration and cumulative duration of the SWDs
(Mann—Whitney U-test). These numbers were only
slightly lower in the LEV group (Fig. 4).
Also in SISWDs, no differences could be found
between both groups (Fig. 4). However, SISWDs were
decreased substantially in favor of typical SWDs in
comparison with young GAERS (PN57—PN64) which
had more SISWDs than SWDs.
Discussion
A new approach to drug screening, including the
process of epileptogenesis, may identify new classes
of drugs.22,23 LEV is a novel AED with potential anti-
epileptogenic properties, which was discoveredusing non-conventional drug screening. It sup-
presses kindling development at doses devoid of
adverse effects with persistent reduction in after
discharge duration after termination of the treat-
ment.7 In the SER-model, LEV was administered
before the appearance of spontaneous seizures
and was terminated at the expected age for seizure
expression, which resulted in a lower seizure num-
ber in pre-treated animals.8 In the present study, we
found that chronic LEV administration induced a
decrease in epileptiform events (SWDs and SISWDs)
in young GAERS (PN57—PN60), which persisted
immediately following cessation of treatment
(PN61—PN64), but not until adulthood.
In GAERS, SWDs strictly correlate with the occur-
rence of clinical absences,18 which was also
observed in this study. However, behavioral absence
seizures can be subtle as they mostly appear during
quiet wakefulness.18 Therefore, EEG recordings
were used to quantify the appearance of SWDs. In
our study, we found that typical SWDs are rare in
young GAERS. Only three out of seven young control
GAERS showed typical SWDs on the EEG and none of
the LEV-treated animals (n = 8). SISWDs, however,
were the most prevalent type of discharge on the
EEG during quiet wakefulness. Hence, these more
irregular discharges were taken into account to
quantify the effect of LEV on epileptiform events.
While it is difficult to correlate SISWDs with beha-
vioral arrest because of their short duration
(<1.5 s), it can be assumed that these discharges
are closely related to SWDs and reflect premature
SWDs given their morphological resemblance with
typical SWDs and their strong decrease in favor of
typical SWDs as the rats grow older.
In this study, epileptiform events (SWDs + SISWDs)
were significantly suppressed (difference of 62%)
during chronic LEV treatment in young GAERS
(PN57—PN60) in comparison with control animals.
This is in line with a previous acute study of Bouw-
man et al.,17 which found a similar difference in
SWDs between control and LEV-treated adult rats in
the WAG/RIJ model of absence epilepsy.
The LEV-treated animals displayed less SISWDs
(up to 81%) than the control group even in the
pre-injection hours during PN57—PN60. This could
suggest that there was a slowing down of the epi-
leptogenic processes by early chronic treatment
(PN23—PN60) with LEV. Yet, the lower number of
SISWDs in the pre-injection hours might also be
caused by retention of LEV in the brain from pre-
vious injections, although LEV was already elimi-
nated from the blood plasma.
Interestingly, there was no acute decrease in
SISWDs after injection of LEV (PN57—PN60) and even
the opposite could be observed. This is in contrast
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which a clear decrease in SWDs could be observed
after a single LEV injection.14,16,17 These studies,
which were performed in adult GAERS,16,17 report
the effect of a first and single LEV injection, while
the effect of chronic LEV administration was not
investigated.14 Moreover, several studies dealing
with the chronic administration of LEV in animal
models of temporal lobe epilepsy report increased
functional tolerance towards LEV and some loss of
efficacy after prolonged administration.7,13,24 This
could be a possible reason for the lack of an acute
decrease in SISWDs in rats that were already pre-
treated.
The acute increase in SISWDs on PN59 and PN60
after LEVadministration could represent a flaring up
which stabilized again towards the next day. A trend
for this phenomenon was also observed in the con-
trol group on PN59 (P = 0.066). There was no differ-
ence between recording hours during the last 4
days, when the rats were no longer injected with
saline or LEV (PN61—PN64). Hence, stress after
injection could be a responsible factor for this
increase in SISWDs, although the animals were
accustomed to the handling procedures.
When treatment was stopped, there was no sud-
den increase in epileptiform events (SWDs and
SISWDs). This is in line with previously performed
rat and mice experiments where chronic treatment
with LEV did not lead to withdrawal hyperexcitabil-
ity.24,25 During different time points, epileptiform
events were still significantly lower (up to 66%) in
young LEV-treated GAERS. This difference in number
of absence seizures between controls and LEV-trea-
ted rats is comparable to the study in the SER
model.8 In the SER study, absence seizures were
still decreased 2 weeks after treatment cessation
during the 30-min recording period. However, the
next week there was no longer a significant differ-
ence between the control and LEV-pretreated
group. In the study of Glien et al.,13 spontaneous
partial seizures in the pilocarpinemodel of temporal
lobe epilepsy were also still decreased 1 week after
termination of chronic LEV administration (2 weeks)
in certain rats, this was described as a carryover
effect.
In both LEV and control group, epileptiform
events started to increase on the last days of record-
ing, which can be due to the progressive nature of
absence epilepsy in young GAERS. Still, significant
lower SISWDs (up to 66%) in the LEV group could be
detected on these last days of EEG recording (PN63
and PN64) in comparison with the control group.
Early chronic treatment with LEV in young GAERS
might have caused an initial slowing down of the
epileptogenic processes, which had persistingeffects after treatment termination. The major
metabolite of LEV is pharmacologically inactive,
and other metabolites are produced at levels below
those that are relevant for pharmacological activ-
ities.7 LEV does not interfere with enzyme sys-
tems26,27 and is washed out rapidly (half-life 2—
3 h) after stopping the treatment.7 As we used a
relatively high dose to inject and LEV is already
effective in low doses in GAERS,14 we expect that
relevant therapeutic concentrations are present in
the blood plasma for 8 h. Hence, the prolonged
decrease in epileptiform events on PN61—PN64 is
probably not due to a prolonged acute effect caused
by accumulated LEV or other metabolites.
Early chronic administration of LEV had no effect
on the later expression of SWDs at the age of 4
months. SISWDs have diminished considerably in
both groups; this supports its role as premature
SWDs. Most likely, after discontinuation of the treat-
ment, epileptogenesis could further progress. To our
knowledge, there is only one other study where an
AED, i.e., remacemide was chronically administered
in young GAERS (PN7—PN25) to establish its effect
on SWD development.28 This study failed to demon-
strate an effect of early remacemide treatment on
the expression of SWDs in adult GAERS.28 In the
present study, adult GAERS displayed fewer seizures
and shorter mean SWD durations compared to pre-
viously published experiments in GAERS, which were
monitored only for a short period of time.18 How-
ever, these values were similar to a previous chronic
experiment performed by our group.29 This phenom-
enon of a decrease in seizures during longer record-
ing periods is correlated with the decrease of
vigilance resulting in more sleep episodes and less
and shorter seizures.19,30
Until now, it is not described in what manner LEV
exerts its effect on absence seizures in GAERS. LEV
has no effect on the T-type voltage-activated Ca2+
current,31 a common target for absence epilepsy
drugs. A possible effect of LEV that might contribute
to its action against SWDs in GAERS could be by
progressively decreased firing of the substantia
nigra pars reticulata (SNR) neurons.32 The SNR is
not part of the epileptic circuit underlying absence
seizures, but it may belong to a system participating
in a remote control over seizures.18 Indeed, high-
frequency stimulation of the SNR has been shown to
interrupt SWDs in GAERS33 and intracerebral micro-
injections of GABA mimetics in the SNR suppress
absence seizures.18 A part of LEV’s ability to sup-
press seizures may origin in its effect on neuronal
firing in the SNR, but the anatomical network and
molecular mechanisms by which this is mediated
remains to be demonstrated.25 By this way, LEV
could suppress SWDs in GAERS, but it is not known
410 S. Dedeurwaerdere et al.if this might interfere with epileptogenesis. In
GAERS pups, metabolic increases in SNR compared
to non-epileptic control rats were observed, which
was suggested to reflect a mechanism of prevention
of epileptogenesis in GAERS.34Conclusion
In this study, chronic LEV administration induced a
decrease in epileptiform events in young GAERS
(PN57—PN60), although this was not obtained by a
decrease immediately after injection. This effect
persisted partly after cessation of treatment
(PN61—PN64), which might reflect a slowing of epi-
leptogenic process due to previous chronic treat-
ment with LEV. However, when LEV- and saline-
treated animals grew up, they all developed a simi-
lar expression of spontaneous absence seizures.Acknowledgments
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